Skip to main content
Premium Trial:

Request an Annual Quote

Mayo Clinic Licenses TB Technology from Qiagen

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mayo Clinic today announced it has licensed patent rights from Qiagen that will allow Mayo Medical Laboratories to offer a test for M. tuberculosis complex speciation.

Financial and other terms of the deal were not disclosed.

In an e-mail, Nancy Wengenack, associate professor of Laboratory Medicine and Pathology at the Mayo Medical School College of Medicine, said that the new test will be PCR-based and use fluorescence resonance energy transfer hybridization probes for detection.

In a statement, Mayo said that the Qiagen-based test will expand its current offering of tuberculosis testing, which includes M. tuberculosis complex culture, molecular identification, and drug susceptibility testing.

Mayo also offers PCR-based testing for M. tuberculosis complex directly from specimens and molecular detection of drug-resistance markers for the drugs isoniazid and pyrazinamide.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.